<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633724</url>
  </required_header>
  <id_info>
    <org_study_id>FVT-L0701</org_study_id>
    <nct_id>NCT00633724</nct_id>
  </id_info>
  <brief_title>Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase I Study of Multiple-vaccine Therapy Including Antiangiogenic Vaccine Using Epitope Peptide Restricted to HLA-A*2402 in Treating Patients With Unresectable or Recurrent Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fukushima Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fukushima Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, immune response and
      clinical response of different doses of HLA-A*2402 restricted epitope peptides URLC10, TTK,
      VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      URLC10 and TTK have been identified as cancer specific molecules especially in non small cell
      lung cancer using genome-wide expression profile analysis by cDNA microarray technique. We
      have determined the HLA-A*2402 restricted epitope peptides derived from these molecules. We
      also tend to use the peptides targeting to tumor angiogenesis. VEGF receptor 1 and 2 are
      essential targets to tumor angiogenesis, and we identified that peptides derived from these
      receptors significantly induce the effective tumor specific CTL response in vitro and vivo.
      According to these findings, in this trial, we evaluate the safety, immunological and
      clinical response of those peptides.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effects, dose limiting toxicity, and maximum tolerated dose as measured by CTCAE ver3.0 pre treatment, during study treatment, and 3 months after treatment</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peptides specific CTL responses in vitro</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate as assessed using RECIST criteria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in levels of regulatory T cells</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2</intervention_name>
    <description>Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease characteristics

          1. Advanced or recurrent non small cell lung cancer

          2. Second line or later therapeutic status

        Patient characteristics

          1. ECOG performance status 0-2

          2. Life expectancy &gt; 3 months

          3. HLA-A*2402

          4. Laboratory values as follows 1500/mm3&lt;WBC&lt;15000/mm3 Platelet count&gt;75000/mm3 Bilirubin
             &lt; 3.0mg/dl Asparate transaminase &lt; 99IU/L Alanine transaminase &lt; 126IU/L Creatinine &lt;
             2.2mg/dl

          5. Able and willing to give valid written informed consent

        Exclusion Criteria:

          1. Active and uncontrolled cardiac disease (includes patients with myocardial infarction
             within 6 months before entry)

          2. Pregnancy (woman of child bearing potential)

          3. Active and uncontrolled infectious disease

          4. Adrenal cortical steroid hormone dependent status

          5. Decision of unsuitableness by principal investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsukazu Gotoh, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fukushima Medical University, First department of Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <state>Fuskushima</state>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Suda T, Tsunoda T, Uchida N, Watanabe T, Hasegawa S, Satoh S, Ohgi S, Furukawa Y, Nakamura Y, Tahara H. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci. 2006 May;97(5):411-9.</citation>
    <PMID>16630140</PMID>
  </reference>
  <reference>
    <citation>Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15;10(24):8577-86.</citation>
    <PMID>15623641</PMID>
  </reference>
  <reference>
    <citation>Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9.</citation>
    <PMID>17020992</PMID>
  </reference>
  <reference>
    <citation>Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46.</citation>
    <PMID>15930316</PMID>
  </reference>
  <reference>
    <citation>Watanabe T, Suda T, Tsunoda T, Uchida N, Ura K, Kato T, Hasegawa S, Satoh S, Ohgi S, Tahara H, Furukawa Y, Nakamura Y. Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas. Cancer Sci. 2005 Aug;96(8):498-506.</citation>
    <PMID>16108831</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>August 13, 2013</last_update_submitted>
  <last_update_submitted_qc>August 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fukushima Medical University</investigator_affiliation>
    <investigator_full_name>Hiroyuki Suzuki</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

